Background {#Sec1}
==========

*Stenotrophomonas maltophilia* is one of the 10 most frequently isolated pathogens responsible for hospital-acquired pneumonias (HAPs) in intensive care unit (ICU) patients in western countries \[[@CR1], [@CR2]\], representing approximately 5% of positive pulmonary samples. Previous studies identified several risk factors for developing *S. maltophilia* HAP in critically ill patients, such as prolonged ICU hospitalization associated with invasive procedures, extended periods of mechanical ventilation, or exposure to broad-spectrum antibiotics \[[@CR3]--[@CR5]\]. Therefore, *S. maltophilia* pneumonia occurs preferentially in patients with the poorest prognosis \[[@CR6], [@CR7]\]. However, these studies were conducted from heterogeneous and small cohorts of patients. The severity of *S. maltophilia* HAP and antimicrobial therapy modalities were sparsely reported \[[@CR3], [@CR4]\]. Hence, data are lacking to draw recommendations on the optimal therapeutic strategies against *S. maltophilia* pneumonia.

We undertook a large nationwide multicenter retrospective study with the main objective to demonstrate that modalities of antibiotic therapy, including empirical antimicrobial choice, whether a combination therapy was used, or the duration of the therapy, would influence in-hospital mortality. Secondary objectives were to describe the characteristics of ICU patients with *S. maltophilia* HAP and to draw prognostic factors of these pneumonias.

Methods {#Sec2}
=======

Design of the study and setting {#Sec3}
-------------------------------

The medical records of patients who experienced *S. maltophilia* pneumonia from January 2012 to January 2017 were collected from 25 ICUs of the French Society of Anaesthesia & Intensive Care Medicine (SFAR) and AZUREA networks \[[@CR8]\]. Participating centers and case-mixes are listed in Additional file [1](#MOESM1){ref-type="media"}.

The collected data involved both ICU and hospital stays. Follow-up was stopped either after hospital discharge or death, whichever occurred first.

Participants {#Sec4}
------------

### Eligibility criteria {#Sec5}

All patients aged over 18 years who were admitted to the participating ICUs and presenting with a documented diagnosis of *S. maltophilia* pneumonia during their ICU stay were eligible.

### Source and method of selection {#Sec6}

The patient's files were extracted through French hospital discharge database containing individual records of all hospital stays using International Classification of Disease (ICD-10) for the terms "*Stenotrophomonas maltophilia*" and "pneumonia." In addition, ICU medical charts were cross-checked with microbiology laboratory-specific information systems to ensure exhaustivity.

Each medical record was analyzed by local investigators to determine if clinical, biological, and/or radiological signs of *S. maltophilia* HAP were present, thus excluding respiratory tract colonizations (defined as a positive respiratory sample without clinical, biological, and/or radiological signs of *S. maltophilia* pneumonia). In case of uncertainty, consensus was obtained between local infectious disease specialists and study coordinators (PG, AB) to clarify *S. maltophilia* HAP cases.

### Definitions {#Sec7}

Pneumonia was defined as follows: (i) new or progressive lung infiltrate, (ii) temperature \> 38 °C or \< 36.5 °C, leukocyte count \> 12,000 μl^−1^ or \< 4000 μl^−1^, purulent endotracheal aspirate or sputum, (iii) positive respiratory sample (see below), and (iv) decline in oxygenation \[[@CR9], [@CR10]\]. HAP was defined as a pneumonia not incubating at the time of hospital admission and occurring 48 h or more after admission. Ventilator-associated pneumonia (VAP) was defined as a pneumonia occurring 48 h or more after tracheal intubation \[[@CR9]\].

The clinical cure of *S. maltophilia* pneumonia was defined by the absence of pneumonia criteria 48 h after antimicrobial therapy cessation. Treatment failure was defined as a failure of first-line treatment or death attributable to *S. maltophilia* pneumonia. Recurrence was defined as the onset of new pneumonia criteria associated with a positive respiratory sample with *S. maltophilia* after the initial pneumonia was considered successfully cured.

Empirical antimicrobial therapy was defined as the first agents prescribed for the initial treatment of HAP (effective or not on *S. maltophilia*) finally diagnosed as being caused by *S. maltophilia*. Empirical antimicrobial therapy was considered as effective if the *S. maltophilia* strain cultured from the respiratory sample was susceptible to at least one of the antimicrobial agents. Combination therapy was defined as the administration of at least two antimicrobial agents a priori (before *S. maltophilia* HAP has been confirmed, usually within 48 h) or a posteriori (after *S. maltophilia* HAP has been confirmed) effective on the *S. maltophilia* strain for more than 24 h.

### Data collection {#Sec8}

Usual demographic variables were collected, including previous hospital stays and previous exposure to antimicrobial therapies (agents and durations). Simplified Acute Physiology Score II (SAPSII) and the Sequential Organ Failure Assessment (SOFA) score were assessed.

On the day of *S. maltophilia* HAP diagnosis, the SOFA score was collected, as well as the number and type of invasive devices inserted. The severity of hypoxemia was graded according to the Berlin acute respiratory distress syndrome (ARDS) criteria \[[@CR11]\]. Requirements for high-flow nasal oxygen therapy, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) were reported. Empirical antimicrobial therapy and secondary adaptations were recorded, as were durations.

### Diagnosis of positive bacterial culture {#Sec9}

In case of *S. maltophilia* isolation, the culture was considered to be positive (either mono- or polymicrobial infection) with the following cutoff: (1) for minimally contaminated lower respiratory tract sample with quantitative culture, the threshold was 10^4^ colony-forming units (CFU)/ml for bronchoalveolar lavage (BAL) and the cutoff was 10^3^ CFU/ml for protected specimen brush (PSB) or protected (plugged) telescoping catheter (PTC); (2) nonprotected sample (endotracheal aspirate, ETA) with quantitative culture (10^5^ CFU/ml); or (3) sputum bacteriology with quantitative culture (10^7^ CFU/ml) \[[@CR12]\].

### Antimicrobial susceptibility testing (AST) {#Sec10}

*S. maltophilia* identification characteristics (date of isolation and type of respiratory tract sampling) and antimicrobial susceptibility testing were independently performed by each microbiology laboratory. AST was performed on isolates using disk diffusion or automated testing methods according to guidelines and breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@CR13]\].

Data management {#Sec11}
---------------

Data were collected and managed using Research Electronic Data Capture (REDCap) software \[[@CR14]\]. The database was approved by the institutional review board of the SFAR (IRB00010254-2015-010), which waived the need for signed informed consent of the participants, in accordance with the French legislation on noninterventional studies \[[@CR15]\]. The study was declared on [clinicaltrials.gov](http://clinicaltrials.gov) (NCT03506191). This manuscript was written in accordance with the STROBE statement for the reporting of observational studies in epidemiology.

Statistical analysis {#Sec12}
--------------------

The results are expressed as the number of patients (%) for categorical variables and mean (± standard deviation) or median \[IQR\] for continuous variables.

Prognostic factors associated with time to in-hospital death were studied using the Cox proportional hazard model. Time to in-hospital death was calculated from the diagnostic date of *S. maltophilia* to death. The follow-up was censored at discharge from the ICU and/or the hospital. Baseline prognostic factors were age, SAPS II, mechanical ventilation at diagnosis, VAP, duration of mechanical ventilation before the diagnosis, SOFA score at diagnosis, bacteremia, mono/polymicrobial pneumonia, use of empirical antimicrobial therapy, and use of empirical antimicrobial therapy effective against *S. maltophilia.* Other antimicrobial therapy-related variables were not defined as baseline and were thus entered in the model as time-dependent variables, including time elapsed between sample and effective antimicrobial therapy, use of effective combination antimicrobial therapy, and duration of effective antimicrobial therapy against *S. maltophilia* (monotherapy or combination therapy).

Baseline and time-dependent variables associated (*p* \< 0.05) with outcome in the univariate analysis and that were present at the diagnosis were considered for the multivariate model, and the final model was selected using backward stepwise regression (*p* \< 0.05). Hazard ratios (HR) were calculated accordingly with their 95% confidence intervals (CI).

We compared the time to in-hospital death between patients who received or not an empirical antimicrobial therapy effective against *S. maltophilia* using propensity score framework. The variables used for propensity score estimations were age, sex, SOFA score at diagnosis, SAPS II, and the ICU length of stay before pneumonia diagnosis. The two groups of patients were matched using a 1:1 nearest neighbor matching algorithm with replacement, using a caliper of 0.2 of the standard deviation of the propensity score on the logit scale \[[@CR16]\]. Covariate balance between the two groups was assessed after matching, and we considered an absolute standardized difference (ASD) less than 0.1 as evidence of balance \[[@CR17]\]. Then, time to in-hospital death was compared between matched groups using a Cox proportional hazard model. The 95% confidence intervals of the estimated hazard ratio (empirical antimicrobial therapy yes vs no) were estimated using robust standard error \[[@CR18]\].

Significance was defined as *p* values \< 0.05. Statistical tests were two-sided. Statistical analyses were performed using R 3.5.0 (R Foundation for Statistical Computing, [http://www.R-project.org/](http://www.r-project.org/), Vienna, Austria).

Results {#Sec13}
=======

Population {#Sec14}
----------

Of the 102,316 patients admitted to the 25 ICUs within the study period, 282 (0.27%) with a *S. maltophilia* pneumonia were included (Fig. [1](#Fig1){ref-type="fig"}). Our population was predominantly male (69.9%), with an age of 65 \[56--74\] years, mostly admitted for medical reasons (59.2%) or emergent surgery (29.4%). Severity at admission was illustrated by SOFA score (8 \[5--11\]) and SAPSII (47 \[36--63\]). ICU and hospital lengths of stay were 32 \[19--58\] and 54 \[30--94\] days, respectively. The overall in-hospital mortality rate was 49.7% (Table [1](#Tab1){ref-type="table"}). There was no difference in trends of patient inclusion and distribution over years. 48, 51, 60, 65, and 59 patients were included in 2012, 2013, 2014, 2015, and 2016 respectively with similar distributions in terms of mortality. Fig. 1Flowchart of the inclusion of patients presenting with *Stenotrophomonas maltophilia* hospital-acquired pneumonia. Asterisk indicates that sample can be from lower respiratory tract, blood, wound/skin, or urine Table 1Demographic and baseline characteristics of ICU patients with *Stenotrophomonas maltophilia* hospital-acquired pneumoniaVariablesTotal *N* = 282Gender, male197 (69.9)Age, years65 \[56--74\]BMI (kg m^− 2^)25.3 \[22--28.8\]Reason for ICU admission Medical condition167 (59.2) Scheduled surgery32 (11.3) Emergent surgery83 (29.4) Postoperative period of cardiac surgery60 (21.3)Previous carriage of *S. maltophilia*13 (4.6)Pulmonary comorbidities Chronic obstructive pulmonary disease51 (18.1) Chronic respiratory insufficiency30 (10.6) Cystic fibrosis2 (0.7)Other comorbidities Hypertension147 (52.1) Congestive heart failure66 (23.4) Dialysis-dependent chronic kidney disease8 (2.8) Liver cirrhosis22 (7.8) Insulin-requiring diabetes31 (11) Severe neurologic disability30 (10.6)Habits Active smoking86 (30.5) Chronic alcohol abuse47 (16.7) Drug abuse8 (2.8)Immune comprise conditions (*n*, %) Neutropenia1 (0.3) HIV and/or CD4 count \< 50/mm^3^1 (0.3) Recent or ongoing chemotherapy11 (3.9) Hematologic malignancy16 (5.7) Solid tumor being actively treated20 (7.1) Solid tumor in remission22 (7.8) Immunosuppressive therapy or corticosteroids use \> 0.5 mg/kg \> 30 days34 (12) Innate or acquired immune deficiency1 (0.3)Severity scores SOFA score at admission8 \[5--11\] SAPS II at 24 h47 \[36--63\]Ventilator-associated pneumonia228 (80.8)Duration of ventilation before *S. maltophilia* HAP, days11 \[5--18\]ICU length of stay, days32 \[19--58\]Hospital length of stay, days54 \[30--94\]Number of days between hospital admission and *S. maltophilia* HAP16 \[8--27\]Number of days between ICU admission and *S. maltophilia* HAP11 \[5--19\]Mortality140 (49.7)Mortality directly attributable to *S. maltophilia*34 (24.3)Data are expressed as number and percentage or median \[interquartile range\] as appropriate*BMI* body mass index, *HAP* hospital-acquired pneumonia, *HIV* human immunodeficiency virus, *ICU* intensive care unit, *IQR* interquartile range, *SAPS* Simplified Acute Physiology Score, *SD* standard deviation, *SOFA* Sequential Organ Failure Assessment, *S. maltophilia Stenotrophomonas maltophilia*

Patients had been hospitalized in the ICU for 11 \[5--19\] days at the time of onset of *S. maltophilia* pneumonia. Forty patients (14.2%) presented with a chronic underlying pulmonary disease. Other characteristics of patients are described in Table [1](#Tab1){ref-type="table"}, and invasive devices are reported in Additional file [2](#MOESM2){ref-type="media"}: Table S1 in the online data supplement.

Description of *Stenotrophomonas maltophilia* hospital-acquired pneumonia {#Sec15}
-------------------------------------------------------------------------

Characteristics of *S. maltophilia* HAP are described in Table [2](#Tab2){ref-type="table"}. Briefly, 41.6% of *S. maltophilia* pneumonias were monomicrobial and 80.8% were VAP. Blood culture was concomitantly positive in only 7.1% of cases. Table 2Characteristics of *Stenotrophomonas maltophilia* hospital-acquired pneumoniaVariablesTotal *N* = 282Monomicrobial pneumonia (*S. maltophilia* only) (*n*, (%))117 (41.6)Other microorganisms identified (polymicrobial) (*n*, (%)) *Acinetobacter baumanii*7 (4.3) *Citrobacter* spp.7 (4.3) *Enterobacter* spp.30 (18.3) *Enterococcus* spp.6 (3.7) *Escherichia coli*25 (15.2) *Haemophilus*3 (1.8) *Hafnia alvei*3 (1.8) *Klebsiella* spp.25 (15.2) Methicillin-resistant *Staphylococcus aureus*3 (1.8) Methicillin-sensitive *Staphylococcus aureus*13 (7.9) *Morganella morganii*1 (0.6) *Proteus* spp.7 (4.3) *Pseudomonas aeruginosa*49 (29.9) *Serratia* spp.8 (4.9) *Streptococcus* spp.1 (0.6) Others10 (6.1)*S. maltophilia* pneumonia-related manifestations (*n*, (%)) Associated bacteremia20 (7.1) Associated empyema thoracis25 (8.9) Associated septic shock123 (43.6)Total number of days of norepinephrine infusion (median \[IQR\])0 \[0--6\]Severity of pneumonia Oxygenation level regarding *S. maltophilia* HAP (*n*, (%))  Hypoxemia with PaO~2~/FIO~2~ \> 300 mmHg with PEEP ≥ 5 cmH~2~O45 (16)  Mild ARDS98 (34.7)  Moderate ARDS101 (35.8)  Severe ARDS36 (12.7) Prone positioning (*n*, (%))13 (4.6) ECMO requirement15 (5.3)  Veno-venous8 (53.3)  Veno-arterial7 (46.7)Data is presented as number (%) or median \[IQR\]. Mild ARDS (200 mmHg \< PaO~2~/FiO~2~ ≤ 300 mmHg with PEEP ≥ 5 cmH~2~O), moderate ARDS (100 mmHg \< PaO~2~/FiO~2~ ≤ 200 mmHg with PEEP ≥ 5 cmH~2~O), severe ARDS (PaO~2~/FiO~2~ ≤ 100 mmHg with PEEP ≥ 5 cmH~2~O)*S. maltophilia*, *Stenotrophomonas maltophilia*; *ARDS*, Acute Respiratory Distress Syndrome, was defined according to the Berlin definition; *PEEP*, positive end-expiratory pressure

Microbiological diagnosis methods for isolation of *S. maltophilia* are presented in Additional file [3](#MOESM3){ref-type="media"}: Table S2 in the online data supplement. Patients with *S. maltophilia* VAP had a duration of mechanical ventilation before the onset of pneumonia of 11 \[5--18\] days. *S. maltophilia* pneumonia-related septic shock was present in 123 patients (43.6%) within 48 h of *S. maltophilia* HAP (septic shock attributed to pneumonia by clinicians and without other identified cause in the post hoc analysis). Among these patients who developed septic shock, 38 (30.8%) did not receive initial empirical antimicrobial therapy. Forty-nine percent of patients fulfilled moderate or severe ARDS criteria.

Antimicrobial therapy {#Sec16}
---------------------

The description of antimicrobial therapy modalities is reported in Table [3](#Tab3){ref-type="table"}. Before the onset of *S. maltophilia* pneumonia, patients received 3 \[2--4\] prior antimicrobial therapies for at least 5 consecutive days in ICU. Empirical antimicrobial therapy was a posteriori effective against *S. maltophilia* in 30.1% of cases. The duration of effective antimicrobial therapy on *S. maltophilia* was 11 \[7--15\] days. A combination of antimicrobials effective against *S. maltophilia* was used in 59.4% of patients for 7 \[5--12\] days. Table 3Antimicrobial therapy management related to *Stenotrophomonas maltophilia* hospital-acquired pneumoniaVariablesTotal *N* = 282Number of antimicrobial therapy lines administered within 30 days before diagnosis (median \[IQR\])3 \[2--4\]Number of days with initial ineffective antimicrobial therapy on *S. maltophilia* (median \[IQR\])2 \[2--3.5\]Most commonly prescribed antimicrobial agents before *S. maltophilia* HAP onset (*n*, (%)) Amoxicillin20 (7.1) Amoxicillin--clavulanate61 (21.6) Third-generation cephalosporin93 (33) Cefepime25 (8.9) Ceftazidime17 (6) Ticarcillin4 (1.4) Ticarcillin--clavulanate10 (3.5) Piperacillin15 (5.3) Piperacillin--tazobactam97 (34.4) Carbapenem63 (22.3) Aminoglycoside70 (24.8) Fluoroquinolone40 (14.2) Trimethoprim--sulfamethoxazole9 (3.2) Glycopeptide59 (20.9) Metronidazole32 (11.3) Linezolid31 (11) Others71 (25.2)Empirical antimicrobial therapy (*n*, (%))166 (58.8)Number of antimicrobial agents for empirical antimicrobial therapy (median, \[IQR\])1 \[0--2\]Efficient empirical therapy on *S. maltophilia* (*n*, (%))50 (30.1)Combination antimicrobial therapy (2 or more) targeting *S. maltophilia* (*n*, (%))167 (59.4)Duration of antimicrobial therapy targeting *S. maltophilia*, days (median, \[IQR\])11 \[7--15\]Duration of combined (2 or more) antimicrobial therapy targeting *S. maltophilia*, days (median, \[IQR\])7 \[5--12\]*S. maltophilia* is intrinsically resistant to amoxicillin, amoxicillin/clavulanate, ticarcillin, piperacillin/tazobactam, carbapenems, and aminoglycosides (EUCAST expert rules version 3.1---26 Sept 2016). Data are presented as median, interquartile range (\[IQR\]), or number (percentage) (*n*, (%)) as appropriate*HAP* hospital-acquired pneumonia

Microbiological data {#Sec17}
--------------------

AST of *S. maltophilia* strains is presented in Fig. [2](#Fig2){ref-type="fig"}a. Trimethoprim--sulfamethoxazole (TMP-SMX) (88.1%) and ticarcillin--clavulanate (73.3%) remained highly active against more than two thirds of *S. maltophilia* strains. The main antimicrobial therapies prescribed to treat *S. maltophilia* HAP after identification were TMP-SMX (29%), ciprofloxacin (25%), and ticarcillin--clavulanate (24%) (Fig. [2](#Fig2){ref-type="fig"}b). Fig. 2**a** Antibiotic susceptibility of *Stenotrophomonas maltophilia* strains isolated from the respiratory tract samples (*n* = 282). **b** Efficient antibiotic treatments prescribed to treat *Stenotrophomonas maltophilia* hospital-acquired pneumonia. Antibiotic susceptibility is depicted in percentage (%) of isolates that were susceptible, intermediate, and resistant or when the antibiotic treatment was not assayed

Prognosis {#Sec18}
---------

Treatment failure occurred in 65 patients (23.1%). Recurrence of *S. maltophilia* pneumonia was diagnosed in 48 patients (17.0%). Co-infection with another pathogen, mostly *Pseudomonas aeruginosa* (*n* = 30), was diagnosed in 70 patients (24.8%) during recurrence (Additional file [4](#MOESM4){ref-type="media"}: Table S3).

In univariate analysis, variables associated with the primary endpoint (i.e., time to in-hospital death) were age (HR = 1.025, 95%CI \[1.012; 1.038\], *p* = 0.0001), SAPS II (HR = 1.009, 95%CI \[1.001; 1.018\], *p* = 0.036), and SOFA score at pneumonia diagnosis (HR = 1.099, 95% CI \[1.057; 1.142\], *p* \< 0.0001) (Table [4](#Tab4){ref-type="table"}). The subsequent occurrence of a septic shock was significantly associated with an increased risk of death (HR = 3.070, 95%CI \[1.9; 5.0\], *p* \< 0.0001). Table 4Variables associated with the time to in-hospital deathVariablesUnivariate analysisMultivariate analysisHR \[95%CI\]*p* valueHR \[95%CI\]*p* valueAge1.025 \[1.012; 1.038\]0.00011.02 \[1.01; 1.04\]0.001SAPS II1.009 \[1.001; 1.018\]0.036Mechanical ventilation at diagnosis1.692 \[0.83; 3.46\]0.151VAP0.748 \[0.49; 1.14\]0.178Duration of MV before the diagnosis0.997 \[0.988; 1.006\]0.462SOFA score at diagnosis1.099 \[1.057; 1.142\]\< 0.00011.1 \[1.06; 1.15\]\< 0.001Bacteremia0.814 \[0.41; 1.60\]0.551Monomicrobial pneumonia1.368 \[0.98; 1.91\]0.066Co-infection with *Pseudomonas aeruginosa*0.843 \[0.53; 1.33\]0.464Time elapsed between pulmonary sample and effective antimicrobial therapy0.99 \[0.97; 1.01\]0.434 \< 24 h1 24--48 h1.22 \[0.74; 2\]0.429 \> 48 h1.34 \[0.85; 2.12\]0.204Empirical antibiotic therapy1.019 \[0.73; 1.43\]0.914Subsequent septic shock3.070 \[1.9; 5.0\]\< 0.0001Empirical antibiotic therapy effective against *S. maltophilia*0.839 \[0.52; 1.35\]0.4705Effective combination antimicrobial therapy1.27 \[0.88; 1.83\]0.204Duration of effective antimicrobial therapy against *S. maltophilia*1.03 \[0.98;1.07\]0.243 \< 7 days1 7--14 days1.06 \[0.6; 1.86\]0.842 \> 14 days0.88 \[0.45; 1.71\]0.706Duration of effective combination therapy against *S. maltophilia*0.99 \[0.96; 1.03\]0.679 \< 7 days1 7--14 days0.82 \[0.52; 1.29\]0.393 \> 14 days0.71 \[0.39; 1.29\]0.262*SAPS* Simplified Acute Physiology Score, *VAP* ventilator-associated pneumonia, *MV* mechanical ventilation, *HR* hazard ratio, *S. maltophilia Stenotrophomonas maltophilia*, *SOFA* Sequential Organ Failure Assessment

Neither the duration of treatment nor the use of combination therapy directed against *S. maltophilia* was associated with the primary endpoint (Table [4](#Tab4){ref-type="table"}). Other commonly reported risk factors for *S. maltophilia* HAP (i.e., immunosuppression, chronic obstructive pulmonary disease (COPD), prior antimicrobial therapy) were not statistically associated with time to in-hospital death.

In multivariate analysis, only age (HR = 1.02, 95% CI \[1.01; 1.04\], *p* = 0.001) and SOFA score at *S. maltophilia* pneumonia diagnosis (HR = 1.1, 95%CI \[1.06; 1.15\], *p* \< 0.001) were associated with in-hospital death (Table [4](#Tab4){ref-type="table"}). Subsequent septic shock was not included in the multivariate analysis because it was a consequence and not present at the diagnosis of *S. maltophilia*. The results were similar when only considering VAP in our cohort (*N* = 228) (Additional file [5](#MOESM5){ref-type="media"}: Table S4). Finally, we performed a statistical analysis based on a propensity score to evaluate the effect of an empirical antibiotic therapy effective on *S. maltophilia* on the primary endpoint (Additional file [6](#MOESM6){ref-type="media"}: Table S5). After matching, we compared 48 patients who received appropriate empirical antibiotic therapy versus 222 who did not (Additional file [7](#MOESM7){ref-type="media"}: Table S6). This analysis confirmed the previous results (HR = 0.891, 95%CI \[0.498--1.593\], *p* = 0.697).

Mono- and polymicrobial *S. maltophilia* HAP {#Sec19}
--------------------------------------------

The aforementioned results remained unchanged when considering only monomicrobial *S. maltophilia* pneumonia (*n* = 117) (HR = 1.08, 95%CI \[1.01; 1.15\], *p* = 0.021 for SOFA score at *S. maltophilia* pneumonia diagnosis). Comparisons of characteristics and outcomes between mono- and polymicrobial *S. maltophilia* HAP are provided in Table [5](#Tab5){ref-type="table"}. No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial *S. maltophilia* HAP. A similar number of VAP occurred in both groups, 91 (77.8%) versus 136 (82.9%) (*p* = 0.280) for mono- and polymicrobial HAP respectively. The duration of ventilation prior to *S. maltophilia* HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial *S. maltophilia* HAP. Table 5Characteristics and outcomes comparing patients with mono- versus polymicrobial *Stenotrophomonas maltophilia* HAPsVariables*Sm* only *N* = 117Polymicrobial *Sm* HAP *N* = 164*p* valueGender, male78 (66.7)119 (72.6)0.362Age, years67 \[59--76\]64 \[55--72\]*0.024*BMI (kg m^−2^)24.6 \[21.1--29.6\]25.7 \[22.3--28.4\]0.361Reason for ICU admission*0.024* Medical condition80 (68.4)87 (53) Scheduled surgery8 (6.8)24 (14.6) Emergent surgery29 (24.8)53 (32.3)Previous carriage of *S. maltophilia*5 (4.3)6 (3.7)0.812Pulmonary comorbidities Chronic obstructive pulmonary disease27 (23.1)24 (14.6)0.084 Chronic respiratory insufficiency15 (12.8)14 (8.5)0.245 Cystic fibrosis0 (0)2 (1.2)0.512Prior exposure to carbapenems27 (23.1)37 (22.5)0.723Susceptibility to trimethoprim--sulfamethoxazole97 (82.9)147 (89.6)0.424Severity scores SOFA score at admission8 \[5--11\]8 \[5--11\]0.381 SAPS II at 24 h48 \[37--62\]47 \[36--63\]0.672Ventilator-associated pneumonia91 (77.8)136 (82.9)0.280Duration of mechanical ventilation prior to *S. maltophilia* HAP, days9 \[2--17\]11 \[6--20\]*0.031*ICU length of stay, days28 \[16--49\]36 \[22--60\]*0.034*Hospital length of stay, days45 \[26--80\]59 \[32--98\]0.062Number of days between hospital admission and *S. maltophilia* HAP14 \[8--23\]17 \[8--31\]0.294Number of days between ICU admission and *S. maltophilia* HAP10 \[5--18\]12 \[6--20\]*0.046*Empiric antibiotic therapy67 (57.3)99 (60.4)0.602Combination therapy active on *S. maltophilia*66 (56.4)100 (61.0)0.407Overall in-hospital mortality63 (53.8)74 (45.1)0.228In-hospital mortality according to empiric antimicrobial therapy0.273 Appropriate8 (6.8)16 (9.8) Inappropriate24 (20.5)30 (18.3)Data are presented as median, interquartile range (\[IQR\]), or number (percentage) (*n*, (%)) as appropriate*BMI* body mass index, *HAP* hospital-acquired pneumonia, *SAPS* Simplified Acute Physiology Score, *SOFA* Sequential Organ Failure Assessment, *S. maltophilia Stenotrophomonas maltophilia*

Discussion {#Sec20}
==========

Herein, we report the largest cohort study of critically ill patients developing *S. maltophilia* HAP. Regarding the large screening, the prevalence of *S. maltophilia* HAP remained very low. The majority of *S. maltophilia* HAP was VAP and occurred in patients ventilated for more than 10 days and previously exposed to several antimicrobial therapies. The mortality rate of these patients remained high, but surprisingly, the treatment delay in adequate antimicrobial therapy targeting *S. maltophilia* was not found to be associated with mortality. This observation may be the result of (i) a low virulence of the pathogen, (ii) the underlying condition of the critically ill patient being more contributive to the outcome than *S. maltophilia* HAP itself, or (iii) a 24- to 48-h delay in the treatment of *S. maltophilia* HAP had no real impact. Finally, if SAPSII and SOFA score were independently associated with mortality, no specific pneumonia or antimicrobial therapy-related factors impacted the outcome.

Our study population shares common features with previously published reports \[[@CR3], [@CR4], [@CR6], [@CR7], [@CR19]--[@CR23]\]. Indeed, *S. maltophilia* pneumonia develops in high-risk phenotypes patients, i.e., long ICU/hospital length of stay and duration of mechanical ventilation. Despite a mortality rate of approximately 50%, it is difficult to delineate direct attributable mortality of *S*. *maltophilia* HAP from mortality linked to underlying diseases \[[@CR24]\]. Indeed, the prolonged ICU length of stay preceding *S*. *maltophilia* isolation and the number of prior antimicrobial therapies suggest noticeable patient frailty and complicated medical history. These factors have been associated to high mortality in patients with resistant bacteria in ICU \[[@CR25]\]. *S*. *maltophilia* HAP could also be perceived as a final septic insult in long-stayer patients, promoting care withdrawal from the medical team.

Previous studies that included a small number of patients \[[@CR3], [@CR4], [@CR6], [@CR19]--[@CR23], [@CR26]--[@CR31]\] suggested that immune-compromised conditions, COPD, prior cardiac surgery, or prior antimicrobial therapy were risk factors for *S. maltophilia* HAP. Conversely, our large series of mixed ICU patients did not confirm these elements. This implies that the involvement of *S. maltophilia* in late onset HAP should be considered and be kept in mind by all critical care physicians. However, in our series, initial antimicrobial therapy inactive against *S. maltophilia* was not a risk factor for in-hospital mortality, arguing against a systematic coverage of *S. maltophilia* by empirical antimicrobial therapy in this setting.

Although the prolonged duration of antimicrobial treatment is a well-known risk factor for emergence of multidrug resistant (MDR) bacteria \[[@CR32]\], it did not appear to be discriminant in our study, irrespective of the class of antimicrobial agent previously administered. These results are in accordance with previously published literature on continuation or de-escalation of beta-lactam antibiotics and emergence of MDR \[[@CR31]\]. Indeed, different regimens were used in our population, with various durations of treatment before *S. maltophilia* HAP diagnosis without apparent consequences on *S. maltophilia* emergence and susceptibility profiles. Soubirou et al. found that the increase in use of antimicrobial class was an independent predictor of *S. maltophilia* emergence in VAP \[[@CR33]\]. It is however conceivable that some patients of our cohort may be colonized with other non-fermenting Gram-negative bacilli. Actually, almost 20% of patients had COPD or chronic respiratory insufficiency and might be regularly exposed to antibiotics. Nseir et al. and Saugel et al. reported 63% and 25% respectively incidence of COPD patients with *S. maltophilia* pneumonia \[[@CR3], [@CR4]\].

Despite clinical signs of HAP, only 59% of patients readily received empirical antimicrobial therapy (Additional file [4](#MOESM4){ref-type="media"}: Table S3). This highlights the variable implementation and adherence to antimicrobial bundles of care and stewardship programs \[[@CR34]--[@CR36]\]. Pathmanathan et al. previously reported no measurable impact of antibiotic therapy in patients without evidence of consolidation which suggests colonization \[[@CR23]\]. In our study, colonization was excluded. Although it is currently suggested to start antibiotics early in patients with suspected VAP \[[@CR37]\], physicians may have been expecting a definitive identification with the resistance profile of microorganisms possibly involved to restrain the use of broad-spectrum antibiotics, especially in patients previously exposed to several antibiotic regimens. Tracheobronchitis and pneumonia may also be hard to be differentiated and need time to be distinguished.

Of note, the interplay between resistance and virulence remains complex \[[@CR38]\]. In these patients already exposed to several series of antimicrobial therapies, with an extended hospital length of stay, the likelihood of MDR bacteria involvement was very high. Moreover, due to its natural resistance to multiple antimicrobial agents, only one third of empirical antimicrobial therapies was actually effective against *S. maltophilia.* Conversely to other authors \[[@CR39]\], but in accordance with studies on *Pseudomonas aeruginosa* VAP, the delayed administration of effective antimicrobial treatment was not statistically associated with increased mortality \[[@CR40], [@CR41]\].

The duration of *S. maltophilia* HAP antimicrobial therapy is still subject to debate. The comparison of short (\< 8 days) versus prolonged (8 days and greater) antibiotic course could not properly be investigated in our study because of its design. Chastre et al. demonstrated that an 8-day course of antibiotic therapy for VAP was not inferior to a longer duration, but only 0.8% of patients had an *S. maltophilia* VAP \[[@CR42]\]. However, it was suggested that patients infected with difficult-to-treat pathogens, immunocompromised patients, and patients at high risk for relapse may require a longer duration of antibiotic therapy. In our study, we identified neither the duration of antimicrobial treatment nor the combination of antibiotic therapies as significant risk factors for in-hospital death. Low virulence of *S. maltophilia* strains may partially explain these findings. In a recent retrospective study focused on the interest of combination therapy, Shah et al. reported that combination of antibiotic therapies yielded similar clinical efficacy and resistance development compared to monotherapy \[[@CR43]\].

Optimal antimicrobial against *S. maltophilia* HAP may raise some concerns. The *S. maltophilia* strains in our study had a preserved susceptibility to ticarcillin--clavulanate and TMP-SMX, 73 and 88% respectively as expected \[[@CR44]\]. However, only 29% of *S. maltophilia* HAP were treated with TMP-SMX. These discrepancies may be related to ICU physicians' habits, the fear of TMP-SMX-related side effects, and the type of antibiotics administered prior to occurrence of *S. maltophilia* HAP. The use of fluoroquinolones could have been considered easier. When prescribed, TMP-SMX was combined with another antibiotic effective on *S. maltophilia* in 80% of cases. In addition, antimicrobial agent shortages change antimicrobial therapy armamentarium, with a cessation of manufacture of ticarcillin--clavulanate in 2015 \[[@CR45]\]. Although ceftazidime/avibactam has poor activity on *S. maltophilia* \[[@CR46]\], it may restore the susceptibility to aztreonam through the inhibition of the L2 β-lactamase in vitro \[[@CR47]\]. The clinical efficacy of this combination has been reported in a case report of a transplant renal patient \[[@CR48]\].

Augmented renal clearance can alter the pharmacokinetics and pharmacodynamics (PK/PD) of several antimicrobial agents, mainly ß-lactams \[[@CR49]\]. The detailed dosages of antimicrobial agents and the measured creatinine clearance were not collected in the present study. However, TMP-SMX and fluoroquinolones were the most prescribed agents. Their plasma concentrations are not dramatically influenced by augmented renal clearance and not easily monitored in daily practice.

Limitations {#Sec21}
-----------

Our study differs from previous studies, where patients with and without *S. maltophilia* infection were compared. We did not consider *S. maltophilia* colonizations but only HAP, unlike previous studies \[[@CR4]\]. In the case of a polymicrobial sample, it is uncertain which bacteria were responsible for the HAP. One may argue that our study suffers from inaccurate diagnoses differentiating between VAP and ventilator-associated tracheobronchitis due to its retrospective design using ICD codes. We acknowledge that the diagnosis method (ETA versus BAL or PSB) may influence the detection of *S. maltophilia*. This was a pragmatic study that describes different ICU practices, and to date, there is no formal evidence of improved outcomes depending on the diagnosis method used \[[@CR50]\]. Despite strict inclusion criteria, and search for consensus in case of debatable case, it is possible that the physician's judgment and diagnosis reported in the medical record were inaccurate. However, 80% of HAP were VAP in our study and excluding non-ventilated patients did not alter the observed results.

Conclusions {#Sec22}
===========

*S. maltophilia* HAP had a very low incidence in critically ill patients but was associated with high mortality rate in this large multicenter study. Its onset is hard to predict because of lack of specific risk factors but occurs mainly in long-stay ICU patients. The present study did not provide evidence of a significant effect of delay, duration, or combination of antimicrobial therapy on mortality. Efforts in developing novel and effective approaches for prevention are warranted.
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ARDS

:   Acute respiratory distress syndrome

AST

:   Antimicrobial susceptibility testing

BAL

:   Bronchoalveolar lavage

CFU

:   Colony-forming units

ETA

:   Endotracheal aspirate

HAP

:   Hospital-acquired pneumonia

ICU

:   Intensive care unit

MDR

:   Multidrug resistant

PSB

:   Protected specimen brush

PTC

:   Protected (plugged) telescoping catheter

SAPS

:   Simplified Acute Physiology Score

SOFA

:   Sequential organ failure assessment

TMP-SMX

:   Trimethoprim--sulfamethoxazole

VAP

:   Ventilator-associated pneumonia
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Take-home message {#FPar1}
=================

In critically ill patients with *Stenotrophomonas maltophilia* hospital-acquired pneumonia, delay to appropriate antimicrobial treatment, combination antimicrobial therapy, or prolonged antimicrobial therapy may not be associated with increased survival.
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